Latest news with #gastrointestinal
CNN
5 days ago
- Health
- CNN
More than 130 passengers fall ill on Royal Caribbean cruise
(CNN) – More than 130 cruise ship passengers reported suffering from a gastrointestinal disease after setting sail from Los Angeles on July 4. The cause of the outbreak has not been determined. The US Centers for Disease Control and Prevention says 134 passengers on Royal Caribbean's Navigator of the Seas — or 3.4 percent of the cruise's total passenger list of 3,900 people — reported feeling ill. Seven members of the crew were also affected, out of a total of 1,266 staff members. The outbreak was reported to the CDC's Vessel Sanitation Program (VSP) on July 11 when the weeklong Royal Caribbean cruise returned to Los Angeles to dock after the trip was over. According to records compiled by the VSP, there have been 18 outbreaks of gastrointestinal illness on cruise ships under the program's jurisdiction so far this year, mainly related to Norovirus. That's the same number of outbreaks reported all of last year, according to incidents logged by the CDC. While it's unclear what caused the outbreak on the Royal Caribbean ship, passengers experienced diarrhea, vomiting and abdominal cramps, the CDC said in a post this week about the Navigator of the Seas outbreak. In April, about 250 passengers on the Queen Mary 2 reported coming down with the highly contagious norovirus. That disease has a reputation as 'the cruise ship virus,' infectious disease expert Dr. William Schaffner, of Vanderbilt University Medical Center, told CNN Travel earlier this year. That's because it spreads easily, and anyone in close quarters — like cruise ships — is extra susceptible. Such outbreaks also frequently occur in schools and jails — wherever large groups of people gather in tight spaces. But the CDC hasn't determined yet if the culprit on the Navigator of the Seas was norovirus. 'The health and safety of our guests, crew, and the communities we visit are our top priority,' a Royal Caribbean Group spokesperson told CNN Travel. 'To maintain an environment that supports the highest levels of health and safety onboard our ships, we implement rigorous cleaning procedures, many of which far exceed public health guidelines.' The CDC says Royal Caribbean reported boosting its cleaning and disinfection procedures and also collected specimens from infected passengers, after isolating anyone who was ill. CNN wellness expert Dr. Leana Wen said that while infectious diseases can be 'very unpleasant,' they typically 'pass within 1 to 2 days.' While the cause remains unknown in this case, Dr. Wen reiterated that precautions such as thorough hand washing are critical. She also noted that norovirus is not killed by alcohol-based hand sanitizers that are commonly used.
Yahoo
5 days ago
- Health
- Yahoo
More than 130 people sickened on Royal Caribbean cruise
(WJW) — A gastrointestinal outbreak aboard a Royal Caribbean cruise ship sickened more than 130 people. It happened earlier this month, according to the Centers for Disease Control and Prevention (CDC), on a round-trip from Los Angeles to Mexico. Teen killed in 'calculated, targeted' shooting in South Euclid The outbreak occurred aboard the Navigator of the Seas during its July 4–11 voyage, with 134 of 3,914 passengers and 7 of 1,266 crew members reporting symptoms such as diarrhea, vomiting, and abdominal cramps, the CDC reported. The cruise line reported the outbreak on July 11, the same day the ship returned from its voyage. SEE IT: Unique deer making rounds in local community In response, Royal Caribbean International implemented increased cleaning and disinfection procedures, collected stool specimens for testing, and isolated affected passengers and crew members. The exact cause of the outbreak remains under investigation. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Medscape
10-07-2025
- Health
- Medscape
Are IV Proton Pump Inhibitors Overused in Upper GI Bleeding?
TOPLINE: Nearly 70% of patients with acute upper gastrointestinal (GI) bleeding and low-risk or no peptic ulcer disease received intravenous (IV) proton pump inhibitors (PPIs) inappropriately, leading to longer hospital stays. METHODOLOGY: Current guidelines recommend transitioning from IV to oral PPIs after esophagogastroduodenoscopy (EGD) if no high-risk stigmata are found and stopping PPIs in patients with upper GI bleeding from causes other than peptic ulcer disease. Researchers conducted a retrospective cohort study of patients hospitalized for acute upper GI bleeding between January 2014 and December 2019. All patients were started on continuous or intermittent IV PPI and underwent EGD that showed a gastric or duodenal ulcer with low-risk signs or lesions unrelated to ulcer disease. Inappropriate use was defined as any continuous IV PPI infusion lasting more than 4 hours after EGD or any intermittent dose administered after the procedure. TAKEAWAY: Researchers analyzed 253 patients (mean age, 62 years; 57% women; 35% White/Caucasian), of whom only 79 (31%) received appropriate PPI therapy, whereas 174 (69%) received it inappropriately (55 on continuous IV PPI infusion and 119 receiving excess intermittent doses). Patients with peptic ulcer disease with low-risk stigmata received an average of five excess IV PPI doses, and those on continuous infusions received an average of 41 additional hours of treatment. Among patients with lesions unrelated to peptic ulcer disease or with no lesions at all, those receiving twice daily IV PPI dosing averaged six extra doses, and those on continuous infusion received an average of 34 additional hours of therapy. At baseline, hemoglobin levels were slightly lower in the inappropriate therapy group than in the appropriate group (7.9 vs 8.7 g/dL). Patients receiving appropriate therapy had a shorter hospital stay than those receiving inappropriate therapy (4 vs 7 days; P = .001). IN PRACTICE: 'We believe that educating practitioners on the appropriate use of PPI therapy in the context of the endoscopic lesion that was believed to have caused bleeding is a critically important next step,' the authors wrote. SOURCE: This study was led by Michael M. Sutton, MD, University of Oklahoma Health Sciences Center, Oklahoma City. It was published online in the Journal of Clinical Gastroenterology. LIMITATIONS: The retrospective design may have introduced biases, such as ascertainment bias, as verbal recommendations for discontinuing IV PPI therapy might not have been documented. The single-center setting limits the generalizability of the findings. DISCLOSURES: This study was supported in part by grants from the National Institutes of Health — the National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of General Medical Sciences, and the National Center for Advancing Translational Sciences. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
CNA
06-07-2025
- Health
- CNA
Singapore evaluates use of some Traditional Chinese Medicine treatments alongside Western medicine
Singapore is evaluating 18 proposals under a sandbox initiative to incorporate certain traditional Chinese medicine treatments into public healthcare. These include how Chinese medicines can be integrated with conventional treatments for conditions like gastrointestinal disorders. The health ministry says it's taking a measured approach to their implementation in public healthcare institutions here for one to two years as patient safety is a priority. Sabrina Ng reports.
Yahoo
28-06-2025
- Business
- Yahoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?
Phathom Pharmaceuticals, Inc. () is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company's loss has recently broadened since it announced a US$334m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$346m, moving it further away from breakeven. Many investors are wondering about the rate at which Phathom Pharmaceuticals will turn a profit, with the big question being 'when will the company breakeven?' We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Consensus from 8 of the American Pharmaceuticals analysts is that Phathom Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$95m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 68%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. We're not going to go through company-specific developments for Phathom Pharmaceuticals given that this is a high-level summary, however, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment. View our latest analysis for Phathom Pharmaceuticals Before we wrap up, there's one issue worth mentioning. Phathom Pharmaceuticals currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag. There are key fundamentals of Phathom Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Phathom Pharmaceuticals, take a look at Phathom Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should further examine: Valuation: What is Phathom Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Phathom Pharmaceuticals is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Phathom Pharmaceuticals's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
